Skip to main content
37°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sesen Bio, Inc.
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
March 02, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
February 28, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
February 21, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
February 16, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
February 16, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
February 15, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
February 14, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
February 02, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Receives NASDAQ Delisting Notice
January 30, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
January 26, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
January 19, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics
January 04, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
December 29, 2022
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
September 21, 2022
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™
December 09, 2021
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™
August 02, 2021
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 18, 2021
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Participate in Fireside Chat at the 2021 Jefferies Virtual Healthcare Conference
May 27, 2021
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity “Horizons in Oncology” Virtual Conference
April 08, 2021
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.